Azenta Inc provides biological and chemical sample exploration and management solutions, using precision automation and cryogenics to develop automated ultra-cold storage... Show more
Azenta, Inc. (AZTA), a provider of sample management and multiomics solutions for the life sciences industry, saw its stock plummet 23.82% in the most recent completed trading session. Shares closed at $18.75, down sharply from the prior close of $24.61. The steep decline stemmed from disappointing Q2 fiscal 2026 results released before the market open, highlighting execution shortfalls and softer demand.
Azenta reported Q2 revenue from continuing operations of $145 million, up just 1% year-over-year but down 3% organically after adjusting for foreign exchange and the UK Biocentre acquisition. This fell short of analyst expectations of $148.75 million. Non-GAAP diluted EPS came in at a loss of $0.04, missing forecasts of $0.11 and reversing the prior year's $0.01 profit. Adjusted EBITDA dropped 36% to $8 million, with margins contracting 320 basis points to 5.4% due to lower fixed-cost absorption, Automated Stores rework costs, and inventory reserves.
The results reflected cautious demand, particularly in North America, with declines in Sanger Sequencing for Multiomics and core products like Automated Stores and Cryogenic Systems in Sample Management Solutions. A massive $149 million non-cash goodwill impairment—$112.4 million in Multiomics and $36.6 million in Sample Management—further pressured GAAP earnings, leading to an operating loss of $165.8 million.
Compounding the miss, Azenta slashed its FY2026 outlook. Total reported revenue is now projected at $603–$621 million, with organic growth revised to -2% to +1% from prior 3–5% growth. Sample Management faces low-single-digit growth instead of mid-single-digits, while Multiomics shifts to mid-single-digit decline. Adjusted EBITDA margins are expected down 125 bps to flat, versus prior expansion guidance. Free cash flow outlook softened to 10–15% improvement. Management cited execution gaps and demand caution, prompting leadership changes and operational focus.
Volume spiked to 964,691 shares, above the average of approximately 900,000, signaling heightened investor reaction to the earnings disappointment. The plunge diverged from broader indices, which ended modestly lower, and biotech peers tracked by ETFs like IBB and XBI, which posted smaller losses. AZTA breached key technical support near $23–$24, its recent moving averages, and the 52-week low around $19.87, accelerating downside momentum in the healthcare equipment sector.
Tickeron’s Trending AI Robots page showcases the platform’s top-performing AI-driven trading bots under current market conditions. Tickeron offers hundreds of AI bots scanning thousands of tickers across diverse strategies, timeframes, and performance metrics, from momentum and mean reversion to sector-specific plays. The curated trending section highlights only the strongest live performers, helping traders identify tools with proven edge amid volatility like today’s biotech sell-off. Explore these bots for automated insights on AZTA and peers—elevate your strategy with data-backed automation today.
Investors will monitor Azenta’s progress on operational execution, including Multiomics transformation, leadership enhancements, and cost discipline. Upcoming Q3 fiscal 2026 earnings, expected in early August, represent a key test of demand recovery and guidance delivery. Analyst consensus holds an Outperform rating with a $35–$41 average target, though recent cuts reflect caution. Sector risks include biotech funding pressures and economic sensitivity, while opportunities lie in recurring revenues from sample repositories and consumables. Uncertainties around B Medical Systems divestiture and long-range plan extension to 2029 add layers to watch.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
AZTA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 41 cases where AZTA's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
The RSI Indicator entered the oversold zone -- be on the watch for AZTA's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AZTA advanced for three days, in of 287 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 164 cases where AZTA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Momentum Indicator moved below the 0 level on May 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AZTA as a result. In of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for AZTA turned negative on May 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .
AZTA moved below its 50-day moving average on May 06, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for AZTA crossed bearishly below the 50-day moving average on May 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AZTA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.532) is normal, around the industry mean (8.208). P/E Ratio (42.431) is within average values for comparable stocks, (105.042). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.220). Dividend Yield (0.000) settles around the average of (0.022) among similar stocks. P/S Ratio (1.387) is also within normal values, averaging (27.522).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. AZTA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AZTA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of automation, vacuum and instrumentation solutions
Industry PharmaceuticalsOther